Retatrutid in Sweden: when will the triple agonist arrive and what is expected to cost

04 May

Retatrutid Sweden is one of the hottest topics in obesity medicine right now. Eli Lilly’s experimental triple agonist activates three hormone receptors simultaneously — GIP, GLP-1 and glucagon — and showed in phase 2 studies an average weight loss of 24.2% of body weight in 48 weeks. It is a number that no previous drug class has come close to.

But when can Swedish patients actually get access to retatrutid, and what will it cost? These are the questions that thousands of overweight and obese people are currently asking.

Parameter	Return time	Tirzepatid (Mounjaro)	Semaglutide (Ozempic/Wegovy)

|Mechanism|GIP + GLP-1 + glucagon|GIP + GLP-1|GLP-1|

|Weight loss (clinical studies)|~24% (phase 2)|~22% (SURMOUNT-1)|~15% (STEP 1)|

|Phase|Phase 3 is ongoing|Approved in the EU|Approved in the EU|

|Availability in Sweden|Not approved|Limited, 2024|Available|

|Expected monthly cost|Unknown, probably SEK 2,000–4,000|SEK 3,000–4,500|SEK 1,500–3,500|

|Dosage|Once/week (injection)|Once/week (injection)|Once/week (injection)|

—

How retatrutide works as a triple agonist

Retatrutide differs fundamentally from previous generations of weight loss drugs by affecting three separate receptor systems. The GLP-1 receptor reduces appetite and slows gastric emptying. The GIP receptor enhances insulin release and contributes to fat burning. The glucagon receptor — and this is where retatrutide really breaks new ground — increases energy expenditure and accelerates the breakdown of visceral fat.

Phase 2 data published in 2023 in the New England Journal of Medicine (n=338, 48 weeks) showed that the highest dose, 12 mg per week, produced an average weight loss of 24.2%. Compared to placebo which was 2.1%, the effect size is remarkable. Important to note: these are phase 2 results, which means a relatively small sample under controlled conditions. The Phase 3 studies, which started in 2023 and 2024, are designed with thousands of participants and will provide a much more robust basis.

The side effect profile is similar to other GLP-1-based drugs: nausea, vomiting and diarrhea are the most commonly reported effects, especially during the ramp-up phase. In phase 2, 9% of participants in the high-dose group discontinued due to adverse events — a figure comparable to tirsepatide at launch but which needs to be confirmed in wider populations.

—

Retatrutid launch — realistic timeline for EU and Sweden

The phase 3 retatrutide program, called TRIUMPH, includes several parallel studies recruiting participants globally. Eli Lilly expects Phase 3 data to be available in 2025-2026. If the results confirm phase 2 efficacy, an application to the EMA (European Medicines Agency) could be submitted in 2026, with possible approval in 2027 at the earliest.

It is important to keep EU approval and actual availability in Sweden separate. The Dental and Medicines Benefit Agency (TLV) decides whether a medicine should be included in the medicine benefit, and that process usually takes another 6-18 months after EMA approval. Tirzepatid (Mounjaro) is an illustrative example: it received EU approval for type 2 diabetes in 2022 and for obesity in 2023, but subsidy decisions and wide availability in Sweden took time.

• TRIUMPH study for obesity: recruitment ongoing, primary endpoint ~2025

• The TRIUMPH study for type 2 diabetes: parallel study with similar timeline

• EMA application: likely in 2026 if data is convincing

• Possible approval in the EU: 2027 in an optimistic scenario

• TLV decision and subsidy in Sweden: 2027–2028 at best

• Practical availability at Swedish pharmacies: realistic in 2028

The optimistic scenario is therefore a launch in Sweden around 2027–2028. Pessimistic scenarios include delays in recruitment, phase 3 safety signals or lengthy price and subsidy negotiations.

—

Retatrutid price — what can Swedish patients expect to pay

Pricing for new weight loss medicine in Sweden is complex and depends on several factors: Eli Lilly’s list price, TLV’s cost-effectiveness analysis and the regions’ negotiation results. No official price for retatrutid yet exists — but we can make educated guesses based on existing market data.

Wegovy (semaglutide) costs approximately SEK 2,500–3,500 per month in Sweden without subsidy. Mounjaro (tirzepatid) is at similar levels. Drug manufacturers tend to price new preparations in line with or just above existing alternatives if efficacy data warrant it.

Given retatrutid’s markedly better weight loss results than semaglutide and slightly better than tirzepatid, a price premium is reasonable to expect. A monthly cost of SEK 3,000–5,000 without subsidy is a likely scenario. If the TLV judges the cost per QALY (quality-adjusted life-year) to be acceptable — which requires the Phase 3 data to hold — the subsidy can lower the patient’s cost significantly.

Without a subsidy, it is a cost that effectively limits access to patients with good finances. The experience with semaglutide shows that global shortages and high prices create parallel trade and unequal access — a pattern that is likely to be repeated with retatrutid.

Always consult a doctor before starting or considering weight loss treatment. Retatrutid is not yet approved and is not available via legal channels in Sweden. The preparation circulating on the gray market has an unknown purity and dose.

—

Eli Lilly retatrutide versus tirzepatid and semaglutide

Eli Lilly has in a short time positioned itself as the leading player in receptor agonist-based obesity treatment. Tirzepatid, sold as Mounjaro (diabetes) and Zepbound (obesity, not yet approved in Sweden), was a paradigm shift. Retatrutid represents the next step in the same line of development.

What clinical data actually compares

The STEP 1 study (semaglutide, 2021, NEJM, n=1,961) showed 14.9% weight loss at 68 weeks. The SURMOUNT-1 trial (tirzepatid, 2022, NEJM, n=2,539) showed 22.5% at 72 weeks for the highest dose. Retatrutide phase 2 (2023, NEJM, n=338) showed 24.2% at 48 weeks. Three important caveats: the studies are not directly comparable due to different study durations, populations and study designs. Head-to-head comparisons are missing.

Side effect profile and tolerability

All three substances share GLP-1-mediated gastrointestinal side effects. The glucagon component of retatrutide adds another dimension — including the potential for muscle loss during severe weight loss and effects on fasting blood sugar. Phase 3 data are needed to quantify these risks in broader populations. Semaglutide has a long safety profile and post-marketing data from millions of patients, which retatrutide lacks.

—

New weight loss medication: what retatrutid means for the treatment landscape

If retatrutide lives up to the promise of phase 2 data, it will fundamentally change the discussion about pharmacological obesity treatment. A weight loss of 20–25% overlaps with the results of bariatric surgery, which historically was the only treatment with that effect size.

It raises legitimately important questions. Will the health care system prioritize recovery time for patients with a BMI over 35 with comorbidities? How is life-long treatment managed — because the effect wears off when the medication is stopped, just like with semaglutide and tirzepatide? And how do we ensure that we don’t create a system where access to the most effective treatments is determined by the thickness of the wallet?

The regions in Sweden have already struggled with the budgetary effects of semaglutide and tirzepatid. Retatrutid, with its likely higher price and potentially even broader indications, amplifies these challenges. TLV’s cost-effectiveness analysis will be decisive.

There is also the issue that is rarely discussed openly: the long-term effects on cardiovascular health, bone calcium, kidney function and muscle mass of >20% weight loss via pharmacology have not yet been mapped at the ten or twenty year level. That’s not an argument against treatment — it’s an argument that phase 3 data and follow-up studies are genuinely necessary before broad prescribing.

—

Frequently asked questions about retreat time in Sweden

Can you buy retatrutid in Sweden today?

No. Retatrutid is not yet approved by the EMA or the Swedish Medicines Agency and cannot be purchased legally in Swedish pharmacies. Preparations sold online under this name have unknown composition and are associated with significant health risks.

What makes retatrutid different from Ozempic and Mounjaro?

Ozempic and Wegovy (semaglutide) activate a receptor, GLP-1. Mounjaro (tirzepatide) activates two, GIP and GLP-1. Retatrutide activates three — GIP, GLP-1 and glucagon — which explains the potentially stronger weight loss effect in early studies.

Who can be eligible for retratru time when it is approved?

Based on how similar drugs have been handled in Sweden, it is likely that retatrutide will initially be targeted at patients with BMI ≥30 with weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea) or BMI ≥35 without comorbidities. Final indications are determined by the approval text.

When is it realistic that retatrutid is available in Swedish pharmacies?

The optimistic scenario is 2027–2028. It assumes that phase 3 data is convincing, that the EMA application is submitted in 2026, that approval is given in 2027 and that TLV quickly deals with the subsidy issue. Realistic planning should start from 2028 or later.

Does the high-cost cover cover recovery time?

It is unknown. TLV decides on subsidies after a medicine has been approved. If retatrutid is judged to be cost-effective — and the phase 3 data provides a strong basis — a subsidy is possible, which would limit the patient’s cost to the high-cost cover’s ceiling of SEK 2,850 per twelve months (2024).

.entry-content